Skip to main content

These findings were recently reported in the Journal of Clinical Oncology.

The good news about childhood cancer is that increasingly more children are surviving. These improved outcomes, however, present new concerns, as long-term health of these individuals may be compromised due to cancer and its treatment. One particular concern is the risk of developing subsequent cancer later in life.

To better define the risk of additional cancer diagnoses for survivors of childhood cancer, researchers recently evaluated 14,358 individuals who had been diagnosed with cancer during childhood. Participants had been diagnosed between 1970 and 1986 and had survived for at least five years.

  • 1,382 of survivors studied (about 9.6%) developed a subsequent cancer. Non-melanoma skin cancer was the most common type of subsequent cancer.
  • Of those with a subsequent cancer, 386 (about 28%) developed a second subsequent cancer. The likelihood of developing two or more subsequent cancers was higher among people who had been treated with radiation therapy as children.
Scroll to Continue

Recommended Articles

Image placeholder title

Relatlimab Anti-LAG-3 Antibody

Is combination immunotherapy with the anti-LAG-3 antibody relatlimab and Opdivo the next advance in melanoma treatment?

Image placeholder title

Blood Cancers and COVID-19 - What You Need to Know

COCID-19 puts individuals with leukemia, lymphoma, myeloma and MPN's at risk - learn how to optimize your care.

Individuals who have survived a childhood cancer diagnosis are at risk for more diagnoses later in life. Given this increased risk, survivors of childhood cancer should talk with their doctor about recommended cancer screening tests.

Reference: Armstrong GT, Liu W, Leisenring W, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Journal of Clinical Oncology [early online publication]. June 27, 2011.

Copyright © 2018 CancerConnect. All Rights Reserved.